Somewhat Positive News Coverage Somewhat Unlikely to Affect Bristol-Myers Squibb (BMY) Share Price

News headlines about Bristol-Myers Squibb (NYSE:BMY) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.1608876050294 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Shares of BMY opened at $62.98 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. The stock has a market capitalization of $102,477.23, a P/E ratio of 20.92, a P/E/G ratio of 1.63 and a beta of 0.96. Bristol-Myers Squibb has a 12-month low of $51.56 and a 12-month high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the firm earned $0.63 earnings per share. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. analysts expect that Bristol-Myers Squibb will post 3.22 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

Several brokerages have recently weighed in on BMY. Citigroup set a $78.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, February 16th. Jefferies Group set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, February 26th. TheStreet downgraded shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. DZ Bank cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, Argus reiterated a “buy” rating and set a $66.43 target price (down from $75.00) on shares of Bristol-Myers Squibb in a report on Wednesday, March 21st. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $66.68.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Bristol-Myers Squibb (BMY) Share Price” was originally posted by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://baseballnewssource.com/2018/04/05/bristol-myers-squibb-bmy-receiving-somewhat-positive-news-coverage-accern-reports/2025347.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Insider Buying and Selling by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.